Harbor Capital Advisors Inc. Boosts Stock Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Harbor Capital Advisors Inc. grew its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 104.8% in the third quarter, Holdings Channel.com reports. The firm owned 7,503 shares of the medical research company’s stock after acquiring an additional 3,840 shares during the quarter. Harbor Capital Advisors Inc.’s holdings in Bio-Rad Laboratories were worth $2,510,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the stock. UMB Bank n.a. grew its position in shares of Bio-Rad Laboratories by 140.6% in the third quarter. UMB Bank n.a. now owns 77 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 45 shares in the last quarter. Wahed Invest LLC lifted its stake in Bio-Rad Laboratories by 14.0% during the first quarter. Wahed Invest LLC now owns 399 shares of the medical research company’s stock worth $138,000 after purchasing an additional 49 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. lifted its stake in Bio-Rad Laboratories by 7.7% during the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 836 shares of the medical research company’s stock worth $289,000 after purchasing an additional 60 shares in the last quarter. Capital Advisors Ltd. LLC lifted its stake in Bio-Rad Laboratories by 193.8% during the second quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company’s stock worth $26,000 after purchasing an additional 62 shares in the last quarter. Finally, Natixis lifted its stake in Bio-Rad Laboratories by 3.4% during the first quarter. Natixis now owns 1,986 shares of the medical research company’s stock worth $687,000 after purchasing an additional 65 shares in the last quarter. 65.24% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have commented on BIO shares. Wells Fargo & Company started coverage on Bio-Rad Laboratories in a research note on Tuesday, August 27th. They set an “equal weight” rating and a $340.00 price target on the stock. Royal Bank of Canada upped their price target on Bio-Rad Laboratories from $446.00 to $469.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. Citigroup upped their price target on Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Finally, StockNews.com upgraded Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research note on Friday. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $391.80.

Insider Activity at Bio-Rad Laboratories

In related news, EVP James Barry sold 623 shares of the stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total value of $205,895.27. Following the transaction, the executive vice president now owns 147 shares of the company’s stock, valued at $48,582.03. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, COO Andrew J. Last sold 3,000 shares of the stock in a transaction on Friday, September 6th. The stock was sold at an average price of $329.94, for a total value of $989,820.00. Following the transaction, the chief operating officer now owns 7,559 shares of the company’s stock, valued at $2,494,016.46. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP James Barry sold 623 shares of the stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $330.49, for a total value of $205,895.27. Following the completion of the transaction, the executive vice president now directly owns 147 shares in the company, valued at $48,582.03. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 17.06% of the stock is currently owned by corporate insiders.

Bio-Rad Laboratories Stock Up 0.1 %

Shares of NYSE BIO opened at $368.92 on Tuesday. The stock has a market cap of $10.28 billion, a P/E ratio of -13.50 and a beta of 0.93. The company has a current ratio of 6.14, a quick ratio of 4.63 and a debt-to-equity ratio of 0.16. Bio-Rad Laboratories, Inc. has a 12-month low of $262.12 and a 12-month high of $372.27. The business’s fifty day simple moving average is $333.99 and its 200-day simple moving average is $308.71.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings data on Wednesday, October 30th. The medical research company reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.16 by $0.85. The business had revenue of $649.70 million for the quarter, compared to analysts’ expectations of $628.18 million. Bio-Rad Laboratories had a positive return on equity of 3.74% and a negative net margin of 30.18%. The company’s revenue for the quarter was up 2.8% compared to the same quarter last year. During the same period last year, the firm earned $2.33 earnings per share. As a group, equities analysts predict that Bio-Rad Laboratories, Inc. will post 9.45 EPS for the current fiscal year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.